ClinicalTrials.gg
RecruitingNCT06653946Updated Oct 29, 2024

the Predictors of Hemorrhagic Transformation Subtypes in Acute Embolic Stroke Patients

A Phase 4 interventional study of Alteplase and Alteplase in Ischemic Stroke and Alteplase Adverse Reaction, sponsored by Kafrelsheikh University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-29.

Sponsored by Kafrelsheikh University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled Jul 2022, registered Oct 2024).
  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
716
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 25 studies testing Tissue Plasminogen Activator in Ischemic Stroke — 4 open to participants now, 4 under way, 3 of them phase 3. Tissue Plasminogen Activator · Ischemic Stroke.

Planned enrollment
4th of 25
716 · median 234
Started
2022
with 3 others
Phase 4
5 of 25
1 open now
Registered
22nd of 25
by date
Lead sponsor
3 of 25
Kafrelsheikh University

Among the 25 studies testing Tissue Plasminogen Activator in Ischemic Stroke, this one is the 4th largest by planned enrollment, is one of 4 that started in 2022, is one of 5 in phase 4, and was the 22nd registered.

Ischemic Stroke

2,625 studies on the registry are indexed under Ischemic Stroke; 982 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

4 of the 25 studies testing Tissue Plasminogen Activator in Ischemic Stroke are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Tissue Plasminogen Activator

Tissue Plasminogen Activator: first FDA approval 1987 (ACTIVASE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 402 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing Tissue Plasminogen Activator in Ischemic Stroke, or all of them as a file.
02

Study summary

The investigators evaluated the impact of AF on different subtypes of post-alteplase hemorrhagic transformation of brain infarction.

Read the detailed description

Investigators conducted a prospective cohort study between July 2021 and July 2023. They screened 1550 patients who presented with AIS and received alteplase and included 716 AIS patients who met the inclusion criteria and were diagnosed based on a thorough clinical assessment, including a detailed medical history, physical examination, and specific brain imaging results and treated with alteplase within four and half hours of stroke onset.

The investigators assessed the patients' follow-up brain imaging to detect the subtypes of hemorrhagic transformation after receiving alteplase.

The study consisted of two distinct groups. The first group consisted of 454 patients who did not experience hemorrhagic infarction, while the second group comprised 262 patients who experienced hemorrhagic infarction.

The investigators evaluated whether the characteristics of ischemic stroke patients, door-to-needle time, and stroke risk factors different types of AF were predictive variables for different subtypes of post-alteplase hemorrhagic transformation of brain infarction.

03

Conditions studied

  • Ischemic Stroke
  • Alteplase Adverse Reaction

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The investigators enrolled individuals of both genders, aged between 18 and 75,
  • All patients had acute first-ever embolic ischemic stroke and were eligible for thrombolysis.
  • All patients had Atrial fibrillation

Exclusion criteria

Exclusion Criteria:

  • The investigators excluded patients who had alteplase
  • The investigators excluded patients who did not receive the total dose of alteplase for any reason.
  • The investigators excluded patients who had a known history of persistent or recurrent CNS pathology (e.g., epilepsy, meningioma, multiple sclerosis)
  • The investigators excluded patients who had recurrent ischemic stroke diagnosed by appropriate clinical history and/or MRI brain findings.
  • The investigators excluded patients with symptoms of major organ failure, active , or an acute myocardial infarction within the previous six weeks.
  • The investigators also excluded pregnant and lactating patients with stroke due to venous thrombosis and stroke following cardiac arrest.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
716 participants (estimated)

Study arms

  • Active comparator
    Hemorragic transformation group

    262 acute ischemic stroke (AIS) patients who had a hemorrhagic transformation of brain infarction after 24-36 hours of receiving alteplase.

    Drug: Alteplase

  • Active comparator
    non-hemorragic transformation group

    454 acute ischemic stroke (AIS) patients did not have a hemorrhagic transformation of brain infarction after 24-36 hours of receiving alteplase

    Drug: Alteplase

Interventions

  • DrugTissue Plasminogen ActivatorStudies of Tissue Plasminogen ActivatorTissue Plasminogen Activator pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit

    Also known as: group A

  • DrugTissue Plasminogen ActivatorStudies of Tissue Plasminogen ActivatorTissue Plasminogen Activator pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit

    Also known as: group B

06

What researchers measure

Primary outcomes

  1. the rate of each AF type in the hemorrhagic infarction type 1 group compared to non HT group

    The investigators will evaluate the rate of each AF type in the hemorrhagic infarction type 1 group compared to non HT group

    Time frame: 48 days

Secondary outcomes

  1. the rate of each AF type in the hemorrhagic infarction type 2 group compared to non HT group

    The investigators will evaluate the rate of each AF type in the hemorrhagic infarction type 2 group compared to non HT group

    Time frame: 48 hours

  2. the rate of each AF type in the parenchymal haematoma type 1 group compared to non HT group

    The investigators will evaluate the rate of each AF type in the parenchymal haematoma type 1 group compared to non HT group

    Time frame: 48 hours

  3. the rate of each AF type in the parenchymal haematoma type 2 group compared to non HT group

    The investigators will evaluate the rate of each AF type in the parenchymal haematoma type 2 group compared to non HT group

    Time frame: 48 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006 May 27;367(9524):1747-57. doi: 10.1016/S0140-6736(06)68770-9. PubMed 16731270 ↗
  • Zeinhom MG, Aref HM, El-Khawas H, Roushdy TM, Shokri HM, Elbassiouny A. A pilot study of the ticagrelor role in ischemic stroke secondary prevention. Eur Neurol. 2022;85(1):50-55. doi: 10.1159/000518786. Epub 2021 Aug 30. PubMed 34515113 ↗
  • Bruno A, Levine SR, Frankel MR, Brott TG, Lin Y, Tilley BC, Lyden PD, Broderick JP, Kwiatkowski TG, Fineberg SE; NINDS rt-PA Stroke Study Group. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology. 2002 Sep 10;59(5):669-74. doi: 10.1212/wnl.59.5.669. PubMed 12221155 ↗

Individual participant data

Plan to share: No — All the data supporting this research's findings may be available from the principal investigator, Mohamed G. Zeinhom, upon reasonable request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Jul 2024, 24 months.

Of 76 non-industry phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 42. This study's 24 months is below that.

Counting every sponsor, half of 85 studies reached it within 31 months; a quarter within 24 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2024
First posted
Oct 23, 2024
StartActual
Jul 1, 2022
Primary completionActual
Jul 1, 2024
CompletionEst.
Nov 1, 2024
Last update
Oct 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06653946
Responsible party
Mohamed G. zeinhom, MD (principal investigator, Kafrelsheikh University) — Principal investigator
First posted
Oct 23, 2024
Start date
Jul 1, 2022
Primary completion
Jul 1, 2024
Completion
Nov 1, 2024 (estimated)
Last update
Oct 29, 2024

Study contacts

mohamed G. Zeinhom, MD
Contact
mohamed_gomaa@med.kfs.edu.eg
2001009606828
sherihan R. ahmed, MD
Contact
sherihan_rezq@med.kfs.edu.eg
2001113432342
mohamed G. Zeinhom, MD
principal investigator · neurology department kafr el-sheikh university

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tissue Plasminogen Activator

Start the discussion